Niclosamide

CAT:
804-HY-B0497-01
Size:
500 mg
  • Availability: 24/48H Stock Items & 2 to 6 Weeks non Stock Items.
  • Dry Ice Shipment: No
Niclosamide - image 1

Niclosamide

  • UNSPSC Description:

    Niclosamide (BAY2353) is an orally active antihelminthic agent used in parasitic infection research[1]. Niclosamide is a STAT3 inhibitor with an IC50 of 0.25 μM in HeLa cells[4]. Niclosamide has biological activities against cancer, inhibits DNA replication in Vero E6 cells[2][3][5].
  • Target Antigen:

    Antibiotic; Parasite; STAT
  • Type:

    Reference compound
  • Related Pathways:

    Anti-infection;JAK/STAT Signaling;Stem Cell/Wnt
  • Applications:

    COVID-19-immunoregulation
  • Field of Research:

    Infection; Cancer
  • Assay Protocol:

    https://www.medchemexpress.com/Niclosamide.html
  • Purity:

    99.90
  • Solubility:

    DMF : 5 mg/mL (ultrasonic)|DMSO : 4.55 mg/mL (ultrasonic)|H2O : < 0.1 mg/mL (ultrasonic;warming;heat to 60°C)
  • Smiles:

    O=C(NC1=CC=C([N+]([O-])=O)C=C1Cl)C2=CC(Cl)=CC=C2O
  • Molecular Weight:

    327.12
  • References & Citations:

    [1]P Andrews, et al. The biology and toxicology of molluscicides, Bayluscide. Pharmacol Ther. 1982;19(2):245-95.|[2]Wei Chen, et al. Niclosamide: Beyond an antihelminthic drug. Cell Signal. 2018 Jan;41:89-96.|[3]Kei Satoh, et al. Identification of Niclosamide as a Novel Anticancer Agent for Adrenocortical Carcinoma. Clin Cancer Res. 2016 Jul 15;22(14):3458-66.|[4]Xiaomei Ren, et al. Identification of Niclosamide as a New Small-Molecule Inhibitor of the STAT3 Signaling Pathway. ACS Med Chem Lett. 2010 Sep 7;1(9):454-9.|[5]Chang-Jer Wu, et al. Inhibition of severe acute respiratory syndrome coronavirus replication by niclosamide. Antimicrob Agents Chemother. 2004 Jul;48(7):2693-6.
  • Shipping Conditions:

    Room Temperature
  • Storage Conditions:

    -20°C, 3 years; 4°C, 2 years (Powder)
  • Clinical Information:

    Launched
  • CAS Number:

    50-65-7